Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])*Julien Carvelli, Ferhat Meziani, Jean Dellamonica et al.|Critical Care Medicine|2022Cited by 29